SynthesisJournal of the National Cancer Institute2017
Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.
Abstract readMeta-Analysis
In one paragraph
Synthesis in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The relative contributions of genetic and non-genetic factors to the risk of neuroblastoma.Pediatric investigation · 2025Review
- Improving neuroblastoma risk prediction through a polygenic risk score derived from genome-wide association study-identified loci.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Lineage specific transcription factor waves reprogram neuroblastoma from self-renewal to differentiation.Nature communications · 2024Article
- Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.Journal of the National Cancer Institute · 2024Article
- Article
- Aberrant splicing in neuroblastoma generates RNA-fusion transcripts and provides vulnerability to spliceosome inhibitors.Nucleic acids research · 2021Article
- Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma.Cancer medicine · 2020Article
- Genome-Wide Association Study for the Identification of Novel Genetic Variants Associated with the Risk of Neuroblastoma in Korean Children.Cancer research and treatment · 2020Article
- Nervous system: Embryonal tumors: Neuroblastoma.Atlas of genetics and cytogenetics in oncology and haematology · 2020Article
- Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.Cell communication and signaling : CCS · 2020Article
- Genetic Predisposition to Solid Pediatric Cancers.Frontiers in oncology · 2020Review
- Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma.Journal of the National Cancer Institute · 2019Article
- Targeting the Chromosomal Passenger Complex Subunit INCENP Induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma.Cancer research · 2019Article
- Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma.American journal of human genetics · 2019Article
- 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype.JCO precision oncology · 2019Article
- Genetic Predisposition to Neuroblastoma.Children (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Eric A HungateAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Mark A ApplebaumAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Andrew D SkolAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Zalman VaksmanAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Maura DiamondAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Lee McDanielAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Samuel L VolchenboumAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Barbara E StrangerAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
John M MarisAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Sharon J DiskinAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Kenan OnelAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Susan L CohnAffiliations of authors: Section of Hematology/Oncology, Department of Pediatrics (EAH, MAA, ADS, SLV, SLC), Section of Genetic Medicine, Department of Medicine (BES), and Institute for Genomics and Systems Biology, Center for Data Intensive Science (BES), University of Chicago, Chicago, IL; Division of Oncology and Center for Childhood Cancer Research and Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA (ZV, MD, LM, JMM, SJD); Department of Pediatrics and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (JMM, SJD); Department of Pediatrics, Hofstra-Northwell School of Medicine and The Feinstein Institute for Medical Research, Manhasset, NY (KO).
Funding
Developing an Oncology Workforce for the 21st Century - Renewal 01K12CA139160 · NCI · UNIVERSITY OF CHICAGO · PI OLOPADE, OLUFUNMILAYO F., SMITH, SONALI · 2010 to 2024
$10.6MNCI NIH HHS K12 CA139160
Abstract
To investigate genetic predispositions for MYCN-amplified neuroblastoma, we performed a meta-analysis of three genome-wide association studies totaling 615 MYCN-amplified high-risk neuroblastoma cases and 1869 MYCN-nonamplified non-high-risk neuroblastoma cases as controls using a fixed-effects model with inverse variance weighting. All statistical tests were two-sided. We identified a novel locus at 3p21.31 indexed by the single nucleotide polymorphism (SNP) rs80059929 (odds ratio [OR] = 2.95, 95% confidence interval [CI] = 2.17 to 4.02, Pmeta = 6.47 × 10-12) associated with MYCN-amplified neuroblastoma, which was replicated in 127 MYCN-amplified cases and 254 non-high-risk controls (OR = 2.30, 95% CI = 1.12 to 4.69, Preplication = .02). To confirm this signal is exclusive to MYCN-amplified tumors, we performed a second meta-analysis comparing 728 MYCN-nonamplified high-risk patients to identical controls. rs80059929 was not statistically significant in MYCN-nonamplified high-risk patients (OR = 1.24, 95% CI = 0.90 to 1.71, Pmeta = .19). SNP rs80059929 is within intron 16 in the KIF15 gene. Additionally, the previously reported LMO1 neuroblastoma risk locus was statistically significant only in patients with MYCN-nonamplified high-risk tumors (OR = 0.63, 95% CI = 0.53 to 0.75, Pmeta = 1.51 × 10-8; Pmeta = .95). Our results indicate that common genetic variation predisposes to different neuroblastoma genotypes, including the likelihood of somatic MYCN-amplification.
Indexed as
Gene AmplificationGenetic Predisposition to DiseaseCase-Control StudiesGene Expression Regulation, NeoplasticGene FrequencyGenome-Wide Association StudyHumansNeuroblastomaN-Myc Proto-Oncogene ProteinPolymorphism, Single NucleotideMYCN protein, humanN-Myc Proto-Oncogene Protein
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.